Filing Details
- Accession Number:
- 0001549595-24-000106
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-30 19:06:21
- Reporting Period:
- 2024-07-30
- Accepted Time:
- 2024-07-30 19:06:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1549595 | Nurix Therapeutics Inc. | NRIX | Pharmaceutical Preparations (2834) | 270838048 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817160 | Gwenn Hansen | C/O Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco CA 94158 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-30 | 3,207 | $0.00 | 42,808 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-07-30 | 2,000 | $0.00 | 44,808 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-07-30 | 3,750 | $0.00 | 48,558 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-30 | 3,408 | $20.67 | 45,150 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2024-07-30 | 3,207 | $0.00 | 3,207 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-07-30 | 2,000 | $0.00 | 2,000 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-07-30 | 3,750 | $0.00 | 3,750 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 19,241 | No | 4 | M | Direct | ||
| 14,000 | No | 4 | M | Direct | ||
| 41,250 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.
- The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
- RSUs do not expire; they either vest or are canceled prior to the vest date.
- The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Billionaire Hedge Funds
